Estimated Read Time: 4 - 5 minutes

Alan's €480 million Series G — backed by Prosus, Index Ventures, and Teachers' Venture Growth — did not happen because the French healthtech company told an exceptional story. It happened because Alan disclosed more than €800 million in ARR in the first quarter of 2026 and now serves over 1.1 million people across an insurance and care navigation platform that investors could underwrite against hard, current numbers. Trase's $107 million seed round, led by ARCH Venture Partners and Red Cell Partners, is the more instructive case for earlier-stage founders: a seed-stage company secured a round most Series A companies would envy, not because the pitch was unusually persuasive, but because the company is building AI agents for regulated healthcare and government-adjacent workflows — a category where investors have already decided, based on data across dozens of other portfolio companies, that the demand is real and durable.

Both rounds reflect the same underlying truth about how capital actually moves in 2026, a year in which Q1 alone saw $300 billion in global venture funding with AI taking 80 percent of that total, even as the top five deals captured nearly three-quarters of all investment. Capital is abundant in absolute terms and brutally scarce in practical terms for any founder without a specific, evidenced answer to the question every investor is now asking by default: why will this work, and what proof do you already have that it does?

The single biggest shift founders need to internalize about raising money in 2026 is that "AI" is no longer a fundable category on its own. A year ago, a strong team and a credible AI thesis were enough to open serious conversations. That is no longer true. Investors have now watched enough AI-branded startups underperform their narrative that the default posture has shifted from optimistic curiosity to skeptical scrutiny. What still gets funded quickly — Alan's ARR, Trase's specific regulated-workflow thesis — is evidence that the company already controls something real: revenue, a workflow, a customer relationship, a technical bottleneck. The pitch deck explains the evidence. It does not substitute for it.

This means the most useful thing a founder can do before raising is not refine the deck. It is generate the evidence the deck will describe. That can be a small number of paying customers who renew and expand. It can be a specific, narrow problem solved so completely that the customer would be genuinely disrupted without the product. It can be usage data that shows retention curves flattening rather than declining. Whatever form it takes, the evidence has to exist before the fundraising conversation starts, because investors in this market are pricing the evidence, not the narrative built around it.

Trase did not pitch itself as a general enterprise AI company. It pitched itself as a company solving tedious, high-volume work specifically inside regulated healthcare and government-adjacent workflows — a thesis narrow enough that investors could evaluate it against a known pattern: regulated markets with real budget and real pain, where AI agents reduce labor-intensive work that humans currently do slowly and expensively. That specificity is what allowed a seed-stage company to raise at a scale typically reserved for companies with revenue traction.

The lesson generalizes. A founder who can describe their company in one precise sentence — naming the buyer, the workflow, and the cost being eliminated — is investable in a way that a founder describing a broad platform vision is not, regardless of how large the eventual market might become. Investors in a selective market are explicitly rewarding legibility: a thesis they can underwrite quickly against patterns they already understand, rather than one they have to take on faith.

Build the evidence first, even if it takes longer than you want. A handful of customers who would be genuinely upset if your product disappeared is worth more to an investor than a large number of users who are mildly satisfied. Define your thesis in a single, specific sentence naming the buyer and the cost you eliminate — vague horizontal positioning is now a liability, not a hedge. And target investors who have already funded the pattern you represent, since a fund that has backed three regulated-workflow AI companies will move faster on a fourth than a generalist fund encountering the thesis for the first time. None of this is about telling a better story. It is about giving the investor less to take on faith.

Managing household finances efficiently is a common frustration among people today. Keeping track of income, expenses, bills, savings, and investments can be overwhelming, leading to stress and confusion. A potential startup idea could be a personalized financial management platform that uses data analytics to create detailed financial reports, provide budgeting suggestions, offer personalized saving tips, and recommend investment opportunities. This platform could integrate with users' bank accounts, credit cards, and investment accounts to gather real-time financial data and provide actionable insights. By leveraging data analytics and machine learning algorithms, the platform can offer personalized financial advice tailored to each individual's financial goals and situation. Market Size: The personal finance software market size is projected to reach $1.57 billion by 2025, with a CAGR of 5.9% according to a report by Grand View Research.

_{Image by freepik}

_{Disclaimer: The startup ideas shared in this forum are non-rigorously curated and offered for general consideration and discussion only. Individuals utilizing these concepts are encouraged to exercise independent judgment and undertake due diligence per legal and regulatory requirements. It is recommended to consult with legal, financial, and other relevant professionals before proceeding with any business ventures or decisions.}

_{Sponsored content in this newsletter contains investment opportunity brought to you by our partner ad network. Even though our due-diligence revealed no concerns to us to promote it, we are in no way recommending the investment opportunity to anyone. We are not responsible for any financial losses or damages that may result from the use of the information provided in this newsletter. Readers are solely responsible for their own investment decisions and any consequences that may arise from those decisions. To the fullest extent permitted by law, we shall not be liable for any direct, indirect, incidental, special, or consequential damages, including but not limited to lost profits, lost data, or other intangible losses, arising out of or in connection with the use of the information provided in this newsletter.}